Quick Answer
Edwards Lifesciences Corp reported Revenue (ASC 606) of $6.07 billion for fiscal year 2025.
Edwards Lifesciences Corp Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $6.07B | +11.5% |
| 2024 | $5.44B | +8.6% |
| 2023 | $5.01B | +12.2% |
| 2022 | $4.46B | -14.7% |
| 2021 | $5.23B | +19.3% |
| 2020 | $4.39B | +0.9% |
| 2019 | $4.35B | +16.8% |
| 2018 | $3.72B | +8.4% |
| 2017 | $3.44B | +15.9% |
| 2016 | $2.96B | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.55B | +14.7% | +1.4% |
| June 30, 2025 | $1.53B | +11.9% | +8.5% |
| March 31, 2025 | $1.41B | +6.2% | +4.3% |
| September 30, 2024 | $1.35B | +8.9% | -1.1% |
| June 30, 2024 | $1.37B | +5.7% | +3.0% |
| March 31, 2024 | $1.33B | -8.9% | +7.0% |
| September 30, 2023 | $1.24B | -5.7% | -4.0% |
| June 30, 2023 | $1.30B | -5.7% | -11.2% |
- Edwards Lifesciences Corp showed an increase of +11.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, Edwards Lifesciences Corp’s revenue (asc 606) has grown by 104.7% (from $2.96 billion to $6.07 billion).
- The most recent figure is from Edwards Lifesciences Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: